Katie S. Murray, DO, MS

Katie S. Murray, DO, is a urologic oncologist at NYU Langone Urology and Bellevue Hospital. She specializes in the surgical management of prostate, testicular, bladder, kidney, and ureter cancers.

Articles by Katie S. Murray, DO, MS

Chandru P. Sundaram, MDUpper Tract Urothelial Carcinoma | September 11, 2024
Drs. Sundaram and Murray highlight the results of a study on robotic nephroureterectomy and bladder cuff excision for UTUC.
View More
Vignesh T. Packiam, MDUpper Tract Urothelial Carcinoma | June 26, 2024
Drs. Packiam and Murray weigh multiple studies exploring gemcitabine/docetaxel as a frontline therapy for UTUC.
Vitaly Margulis, MDUpper Tract Urothelial Carcinoma | June 10, 2024
Drs. Margulis and Murray showcase the ENLIGHTED study examining the efficacy and safety of padeliporfin VTP for LG UTUC.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
Katie S. Murray, DO, MSUrothelial Carcinoma | June 9, 2024
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
Stephan Broenimann, MDUpper Tract Urothelial Carcinoma | May 7, 2024
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Yair Lotan, MDNon-Muscle Invasive Urothelial Carcinoma | May 7, 2024
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Yair Lotan, MDUpper Tract Urothelial Carcinoma | May 7, 2024
Drs. Murray and Lotan highlight a recent multicenter study featuring longitudinal follow-up of UGN-101 for UTUC.
Christopher Wallis, MD, PhD, FRCSCUpper Tract Urothelial Carcinoma | December 18, 2023
Drs. Murray and Wallis discuss optimal patient selection, size criteria, and surgical ablation and chemoablation together.
Katie S. Murray, DO, MSUpper Tract Urothelial Carcinoma | October 2, 2024
Detailing the mitomycin gel adverse events, as well as advice for private practice urologists when offering mitomycin gel.
Katie S. Murray, DO, MSUpper Tract Urothelial Carcinoma | July 24, 2023
Ideal candidates for nephron sparing management for upper tract disease, as well as candidates for mitomycin gel.